Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
Open Access
Abstract
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis that occurs mainly in the third trimester or immediately after delivery; one of its most common symptoms is back pain caused by a vertebral fracture. The pathogenesis of PLO is unclear, and there is no accepted consensus regarding the treatment of PLO. Although treatments with drugs such as bisphosphonate, strontium ranelate, denosumab, and teriparatide were reported, there is no report of a patient with PLO treated with romosozumab. We present the first case of a patient with PLO treated with romosozumab following 4-month teriparatide treatment. A 34-year-old primiparous and breastfeeding Japanese woman experienced severe low back pain 1 month postdelivery. She was diagnosed with PLO on the basis of low bone marrow density (BMD) and multiple vertebral fractures with no identified cause of secondary osteoporosis. She was treated with teriparatide injection for 4 months, but the treatment was discontinued because of the patient feeling severe nausea after every teriparatide injection and the appearance of new vertebral fractures. Thereafter, we used romosozumab for 12 months. After the romosozumab treatment, her BMD was increased from the baseline by 23.6% at L1–L4, 6.2% at the femoral neck, and 11.2% at the total hip. Treating PLO with 12-month romosozumab after 4 months of teriparatide injection remarkably increased the BMD of the lumbar spine, femoral neck, and total hip without subsequent fracture. Romosozumab has potential as a therapeutic option to improve the BMD and reduce the subsequent fracture risk of patients with PLO.Keywords
This publication has 41 references indexed in Scilit:
- Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fracturesJournal of Bone and Mineral Metabolism, 2011
- Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort studyOsteoporosis International, 2011
- Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?Autoimmunity Reviews, 2010
- Treatment with teriparatide in a patient with pregnancy-associated osteoporosisGynecological Endocrinology, 2010
- Pregnancy- and lactation-associated osteoporosis with severe vertebral deformities: can strontium ranelate be a new alternative for the treatment?The Spine Journal, 2009
- A case report: pregnancy-induced severe osteoporosis with eight vertebral fracturesRheumatology International, 2008
- Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitroBone, 2008
- The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatmentReproductive Toxicology, 2006
- Bisphosphonates in pregnancy and lactation-associated osteoporosisOsteoporosis International, 2006
- POST-PREGNANCY OSTEOPOROSIS A SYNDROME ?The Lancet, 1955